Previous 10 | Next 10 |
Gainers: Camber Energy (NYSEMKT: CEI ) +107% . Acacia Communications (NASDAQ: ACIA ) +35% . Electrameccanica Vehicles (NASDAQ: SOLO ) +26% . Xenetic Biosciences (NASDAQ: XBIO ) +16% . iFresh Inc. (NASDAQ: IFMK ) +15% . Atreca (NASDAQ: BCEL ) +15% . Pareteum Corporation (NASDAQ:...
NEW YORK, July 09, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (" Immutep ” or “ Company ”), an Australian biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, has announced an equity financing to ra...
LONDON, UK / ACCESSWIRE / July 2, 2019 / Immutep's AIPAC Phase IIb study of its antigen-presenting cell activator eftilagimod alpha (efti) plus chemotherapy in breast cancer is fully recruited and expected to report top-line data in Q120. The initial tranche of 17 subjects in the first-line ...
226 patients with metastatic breast cancer have been enrolled in the AIPAC study Combination of eftilagimod alpha, an antigen presenting cell (APC) activator, administered in combination with chemotherapy is designed to boost the T-cell immune responses against tumours Read-out of progre...
NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, will host a key opinion leader (KOL) call on novel ...
The Australian Patent Office has granted Immutep (NASDAQ: IMMP ) a new patent (number 2014368420) entitled “Combined Preparations for the Treatment of Cancer”. More news on: Immutep Limited, Healthcare stocks news, Read more ...
SYDNEY, Australia, June 21, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new ...
Recruitment for 2 nd line (PD-1 refractory) NSCLC and 2 nd line HNSCC cohorts of the TACTI-002 trial, conducted in collaboration with MSD, are ongoing Initial data from the TACTI-002 study expected mid-2019 SYDNEY, Australia, June 13, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: ...
Highlights First patient received first dose in INSIGHT-004, a phase I clinical trial Evaluates the combination of eftilagimod alpha with avelumab (BAVENCIO®) in different cancer indications Patient recruitment for the trial is ongoing in Germany, with first data expected in 20...
SYDNEY, Australia, June 03, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to confirm that it was involved...
News, Short Squeeze, Breakout and More Instantly...
Media Release Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA ® (pembrolizumab), MSD’s anti-PD-1 therapy, and standard chemotherapy in first-...
Media Release Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...
2024-07-12 10:45:04 ET QuantumScape Corp (QS) QS is trading UP for the last 5 days, and it at trading at $7.84 with volume of 22,322,158 and a one day change of $0.78 (10.98%). QuantumScape Corp has a 52-week low of 4.67 and a 52-week high of $13.86. The business's 50-day moving ave...